Posted by Michael Wonder on 17 May 2023
Risankizumab for previously treated moderately to severely active Crohn's disease
17 May 2023 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for patients 16 years of age and older with previously treated moderate to severe active Crohn's disease.
Risankizumab is recommended as an option for the treatment of patients 16 years of age and older with moderately to severely active Crohn's disease only if the disease has not responded well enough or lost response to a previous biological treatment, or a previous biological treatment was not tolerated, or the use of a tumour necrosis factor (TNF)-alpha inhibitor is not suitable.
